University of New Mexico psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
University of New Mexico is listed with 8 registered studies counted here, in Albuquerque, United States. By compound: 4 psilocybin, 1 MDMA, 1 LSD and 3 ketamine. By registry status: 2 recruiting, 1 not yet recruiting, 3 completed and 2 withdrawn. By phase: 1 early phase 1, 2 phase 1, 4 phase 2 and 1 not applicable. Reported start years run from 2011 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 8 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 4 |
| MDMA | 1 |
| LSD | 1 |
| Ketamine | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 2 | 25% |
| Not yet recruiting | 1 | 13% |
| Completed | 3 | 38% |
| Withdrawn | 2 | 25% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 13% |
| Phase 1 | 2 | 25% |
| Phase 2 | 4 | 50% |
| Not applicable | 1 | 13% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | NCT07745569 | Not yet recruiting | Phase 2 | 2026-08-31 | Psilocybin |
| Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | NCT07484906 | Withdrawn | Phase 2 | 2026-05-01 | Psilocybin |
| Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder | NCT07506395 | Recruiting | Phase 1 | 2026-05-01 | Psilocybin |
| MDMA for Co-occurring PTSD and OUD After Childbirth | NCT05219175 | Recruiting | Phase 2 | 2024-04-16 | MDMA, LSD |
| Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD | NCT06036511 | Withdrawn | Phase 1 | 2023-12-31 | Ketamine |
| EEG Characteristics in ECT | NCT04022226 | Completed | Early Phase 1 | 2019-10-01 | Ketamine |
| Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence | NCT01534494 | Completed | Phase 2 | 2012-01-01 | Psilocybin |
| Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time | NCT01567852 | Completed | Not applicable | 2011-08-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD | Ketamine